Pediatr. praxi. 2013;14(2):141-142
Significance of ten-valent pneumococcal conjugate vaccine SynflorixTM (PCV10) in the context of new efficacy data
- 1 Klinika infekčních nemocí, Lékařská fakulta UK a Fakultní nemocnice v Hradci Králové
- 2 Department of Psychiatry, University of Cambridge, Cambridge, Velká Británie
- Katedra kinantropologie, Fakulta tělesné výchovy a sportu UK, Praha
Introduction of heptavalent pneumococal conjugated vaccine was followed by substantial reduction of pneumococcal diseases in
children and adults. Research on additional pneumocccal vaccines was inspired by increasing incidence of non-vaccine serotypes. The
registrations derived from non-inferiority to PCV7 have been broadened to real clinical trials. Clinical trial FinIP aimed to the onset of
IPD in Finland has been still the first study confirming the effectiveness of PCV10 against IPD. The reported overall efficacy against vaccine
and non-vaccine serotypes was 93% (95 % CI 75–99). High efficacy of PCV10 against IPD in Finland is promising in terms of similar
epidemiological situation concerning pneumococcal diseases in the Czech Republic.
Keywords: conjugated vaccines, effectiveness, FinIP, clinical trial, invasive pneumococcal disease
Published: May 1, 2013 Show citation
References
- Hsu K, Pelton S, Karumuri S, et al. Population-Based Surveillance for Childhood Invasive Pneumococcal Disease in the Era of Conjugate Vaccine. Pediatr Infect Dis J 2005; 24(1): 17-23.
Go to original source... 
Go to PubMed... - Black S, Shinefield H, Fireman B, et al, and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficcacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-195. Go to original source... Go to PubMed...
- http://www.who.int/immunization/sage/SAGEReplacementReport2011FINAL_nov11.pdf.
- Miller E, Andrews NJ, Waight P, et al. Herd immunity and serotype replacement four years after pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-768. Go to original source... Go to PubMed...
- Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(suppl): S66-76. Go to original source... Go to PubMed...
- Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPwHBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009; 28:(Suppl 4): S89-S96. Go to original source... Go to PubMed...
- http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm.
- Palmu AA, et al. (2012) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. The Lancet. http://dx.doi.org/10.1016/S0140-6736(12)61854-6. Go to original source... Go to PubMed...
- De Wals P, Lefebvre B, Defay F, et al. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012; 30: 6416-6420. Go to original source... Go to PubMed...
- http://www.gsk-clinicalstudyregister.com/index.jsp.
- Vesikari T, et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against carriage and acute otitis media (AOM): design of a cluster-randomised trial. International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD), Foz de Iguacu, Brazil, 11-15 March 2012.
- Vesikari T, Forsten A, Seppa I, et al. Effectiveness of the 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media. ICAAC 2012, San Francisco, USA, September 9 to 12, 2012.
- Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D provide protection against otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: a randomized double blind efficacy study. Lancet 2006; 367: 740-748. Go to original source... Go to PubMed...
- Eskola J, Kilpi T, Palmu A, et al. Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. N Engl J Med 2001; 344: 403-409. Go to original source... Go to PubMed...